A vaccine expert breaks down everything you need to know about the Novavax vaccine.
Rigor académico, oficio periodístico
Artículos sobre AstraZeneca vaccine
Mostrando 61 - 80 de 154 artículos
COVAX, the global vaccine distribution initiative, is well behind its goal of delivering 2 billion doses this year due to under-investment, vaccine nationalism and export restrictions.
The challenge now is to address the understandable concerns and prevent them from contaminating the broader public dialogue on COVID-19 vaccination.
With changing recommendations about AstraZeneca’s COVID-19 vaccine making headlines, many people have questions about its use.
The mechanisms behind vaccine-related and pill-related clots are quite different.
This week’s unwelcome medical advice about the AstraZeneca vaccine is the latest setback to the rollout and the Morrison government.
How do we reasonably and accurately balance the risks of the AstraZeneca vaccine against the benefits? Conceptualising risk can be tricky, but the government’s latest advice is sensible.
This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
The UK’s proposal to give under-30s other vaccines shouldn’t be too disruptive, but in Europe, greater restrictions look likely.
Kenya grapples with two major challenges in the vaccination rollout: access to sufficient doses in light of the global shortage; and vaccine hesitancy.
The vaccine rollout was thrown into fresh uncertainty on Thursday night after the government received medical advice against using the AstraZeneca vaccine for people under 50 because of the very small risk of blood clots.
All vaccines and medications come with risks. But the risks of delaying vaccination are far higher.
Scientists have called it “vaccine-induced prothrombotic immune thrombocytopenia”, or VIPIT. The condition is characterised by a shortage of platelets in the blood.
We need to stop relying on small GP clinics and urgently move towards using mass vaccination hubs like stadiums, schools and parks.
Stephen Duckett on what’s wrong with the rollout
Michelle Grattan discusses the vaccine rollout with Stephen Duckett.
Good news for children and young people, bad news for Johnson & Johnson.
These mistakes have been mainly caused by our leaders giving priority to a good political story over good policy.
The UK says its contract is better – it simply put tougher penalty clauses in place.
Exports of the vaccine continue to be a point of contention between the EU and UK, while newly released US trial results are quickly amended.
These results can help allay previous concerns in Europe about a lack of trial data for older people.
Principales colaboradores
-
Professorial Fellow, University of Canberra
-
Professor of Medicine, University of East Anglia
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Senior Research Fellow in Global Health, University of Southampton
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
-
General Practitioner, PhD Candidate, Bond University
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Professor of Immunology, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Chair in Epidemiology, Deakin University
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Professor and Director of the Clinical Anatomy Learning Centre, Lancaster University
